Table 5 Hyperlactatemia during CPB and postoperative outcome
From: Hyperlactatemia during cardiopulmonary bypass: determinants and impact on postoperative outcome
Univariate analysis (Student's t test) | Correcteda values | |||
|---|---|---|---|---|
Outcome variable | No HL (n = 443) | HL (n = 27) | p | P |
Peak serum creatinine (mg/dl) | 1.3 ± 1.1 | 2.1 ± 1.4 | 0.001 | 0.45 |
MV time (hours) | 22.6 ± 55 | 57.4 ± 68 | 0.015 | 0.41 |
ICU stay (days) | 2.5 ± 3.4 | 5.3 ± 5.4 | 0.012 | 0.04 |
Univariate analysis (RR) | Correctedb values | |||
Outcome variable | No HL (n = 443) | HL (n = 27) | RR (95% CI) | OR (95% CI) |
Prolonged (> 7 days) ICU stay | 18 (4.1%) | 5 (18.5%) | 5.3 (1.8–15.8) | 4.2 (1.04–17) |
Prolonged (> 48 hours) MV | 21 (4.7%) | 9 (33.3%) | 10 (4–25) | 4.9 (1.6–15) |
Surgical revision | 19 (4.3%) | 5 (18.5%) | 5.1 (1.7–14.8) | 2.5 (0.6–9.5) |
Intra-aortic balloon pump | 2 (0.4%) | 3 (11.1%) | 27.5 (4.4–172) | 23 (2.7–207) |
Atrial fibrillation | 75 (17%) | 9 (33.3%) | 2.4 (1.06–5.6) | 1.6 (0.6–4.1) |
Severe lung dysfunction | 6 (1.3%) | 2 (7.4%) | 5.8 (1.1–30.3) | 0.8 (0.1–8.5) |
Sepsis | 9 (2%) | 3 (11.1%) | 6 (1.5–23.7) | 3.6 (0.6–21) |
Composite morbidity index | 36 (8.1%) | 9 (33.3%) | 5.6 (2.4–13.5) | 2.9 (1.03–8.5) |
Hospital mortality | 5 (1.1%) | 3 (11.1%) | 10.9 (2.5–48) | 2.5 (0.37–18) |